Af­ter com­ing out of bank­rupt­cy, Mallinck­rodt pays out $260M to set­tle Ac­thar Gel law­suits

Al­most 18 months af­ter Mallinck­rodt filed for Chap­ter 11 bank­rupt­cy in Oc­to­ber 2020, the com­pa­ny got its re­or­ga­ni­za­tion ap­proved — and is pay­ing out $260 mil­lion right out of the gate in set­tle­ments.

The US De­part­ment of Jus­tice said in a state­ment on Mon­day that the Staines-up­on-Thames-based com­pa­ny is pay­ing out $260 mil­lion to set­tle 2 law­suits against the phar­ma, which al­leged that Mallinck­rodt vi­o­lat­ed the False Claims Act by un­der­pay­ing Med­ic­aid re­bates due for its mul­ti­ple scle­ro­sis drug Ac­thar Gel, and us­ing a foun­da­tion as a way to pay il­le­gal co-pay sub­si­dies in vi­o­la­tion of an­ti-kick­back laws for that drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER